作者
Giuliana Salvatore, Valentina De Falco, Paolo Salerno, Tito Claudio Nappi, Stefano Pepe, Giancarlo Troncone, Francesca Carlomagno, Rosa Marina Melillo, Scott M Wilhelm, Massimo Santoro
发表日期
2006/3/1
期刊
Clinical Cancer Research
卷号
12
期号
5
页码范围
1623-1629
出版商
American Association for Cancer Research
简介
Purpose: Oncogenic conversion of BRAF occurs in ∼44% of papillary thyroid carcinomas and 24% of anaplastic thyroid carcinomas. In papillary thyroid carcinomas, this mutation is associated with an unfavorable clinicopathologic outcome. Our aim was to exploit BRAF as a potential therapeutic target for thyroid carcinoma.
Experimental Design: We used RNA interference to evaluate the effect of BRAF knockdown in the human anaplastic thyroid carcinoma cell lines FRO and ARO carrying the BRAF V600E (V600EBRAF) mutation. We also exploited the effect of BAY 43-9006 [N-(3-trifluoromethyl-4-chlorophenyl)-N'-(4-(2-methylcarbamoyl pyridin-4-yl)oxyphenyl)urea], a multikinase inhibitor able to inhibit RAF family kinases in a panel of six V600EBRAF-positive thyroid carcinoma cell lines and in nude mice bearing ARO cell xenografts. Statistical tests were two sided.
Results …
引用总数
学术搜索中的文章
G Salvatore, V De Falco, P Salerno, TC Nappi, S Pepe… - Clinical Cancer Research, 2006